Oded

(redirected from MYCN)
Also found in: Medical, Acronyms.

Oded

(ō`dĕd), in the Bible. 1 Father of the prophet Azariah. 2 Prophet who interceded for captive Judahites.
References in periodicals archive ?
MYCN is correlated with advanced stage, unfavorable tumor biology and poor outcome even in infants and lower stages.
Adverse prognostic features include patients >12 months of age, MYCN gene amplification, metastatic spread, and a poorly differentiated tumor with a high mitotic-karyorrhexis index.
Next, we evaluated the expression of the Myc network genes including cMyc and Mycn, as well as the Mxd family of Myc antagonists (Mxd1, Mxd2/Mxi1, Mxd3, and Mxd4), in stem and progenitor subpopulations in mice with the Flt3-ITD mutation and littermate WT controls by quantitative real-time PCR (Q-RTPCR) (Figure 2).
Of note, ATM deletion correlates with lower eventfree survival and overall survival in patients affected by NB, independently of MYCN amplification [31].
MYCN down-regulated by miR-375 led to inhibition of tumour growth and tumourigenicity.7 Furthermore, several miRNAs have been shown to function as mediators of metastasis in NB.
[15] Somatic amplification of the MYCN oncogene is responsible for some cases of non-hereditary, early-onset, aggressive, unilateral retinoblastoma.
Jude genomic database, researchers searched for other genes that were abnormally switched on in a virulent form of AML that is driven by an oncogene called MYCN. This gene is a switch that activates a range of other genes.
The International Neuroblastoma Risk Group Consensus Pretreatment Classification Scheme defines prognosis and design treatment programs based on the stage of the tumor (according to the International Neuroblastoma Risk Group Staging System, INRGSS), age at diagnosis, pathology (INPC), and gene expression abnormalities (MYCN gene amplification, 11q aberration, and ploidy) (Table 2) [11].
Overall, histology was favorable based on International Neuroblastoma Pathology Classification; however, fluorescence in situ hybridization showed that tumor cells with and without amplification of the MYCN oncogene coexisted in the biopsied specimen.
In addition, SSTR2 or NET expression did not appear to be correlated with MYCN amplification or p53 mutation status.
Tweddle, "p53, SKP2, and DKK3 as MYCN target genes and their potential therapeutic significance," Frontiers in Oncology, vol.
In the top upstream transcription factors, p53, MYC, and MYCN, were highlighted as upstream regulators involved in the process of cancer (Table S9).